Abstract
Passion fruit (Passiflora edulis Sims f. flavicarpa) is popularly known for its sedative and calming properties and is consumed as a fresh fruit or as a juice. The clinical observation of blood incoagulability associated with excessive consumption of passion fruit juice, in a patient treated with warfarin, prompted the current study to investigate in vitro the presence of blood clotting inhibitors in Passiflora edulis Sims f. flavicarpa extract. After purification process, two compounds of distinct molecular weight and inhibitory action were better characterized. One is a trypsin inhibitor similar to inhibitors from Bowman-Birk family, named PeTI-I12, and other is a compound active in coagulation that prolongs aPTT and PT, but does not change TT. The aim of this study is to provide evidence that passion fruit extract’s components play a role on hemostasis and therefore may be relevant in the handling of patients treated with anticoagulants or suffering hemorrhagic diseases.
Keywords: aPTT, blood coagulation, Bowman-Birk inhibitor, Passiflora edulis, passion fruit, Passifloraceae, trypsin inhibitor, warfarin
Protein & Peptide Letters
Title:Effects of Compounds from Passiflora edulis Sims f. flavicarpa Juice on Blood Coagulation and on Proteolytic Enzymes
Volume: 19 Issue: 5
Author(s): Ana Claudia Sato, Sonia A. Andrade, Marlon V. Brito, Antonio Miranda, Misako Uemura Sampaio, Francisco Humberto de Abreu Maffei and Maria Luiza Vilela Oliva
Affiliation:
Keywords: aPTT, blood coagulation, Bowman-Birk inhibitor, Passiflora edulis, passion fruit, Passifloraceae, trypsin inhibitor, warfarin
Abstract: Passion fruit (Passiflora edulis Sims f. flavicarpa) is popularly known for its sedative and calming properties and is consumed as a fresh fruit or as a juice. The clinical observation of blood incoagulability associated with excessive consumption of passion fruit juice, in a patient treated with warfarin, prompted the current study to investigate in vitro the presence of blood clotting inhibitors in Passiflora edulis Sims f. flavicarpa extract. After purification process, two compounds of distinct molecular weight and inhibitory action were better characterized. One is a trypsin inhibitor similar to inhibitors from Bowman-Birk family, named PeTI-I12, and other is a compound active in coagulation that prolongs aPTT and PT, but does not change TT. The aim of this study is to provide evidence that passion fruit extract’s components play a role on hemostasis and therefore may be relevant in the handling of patients treated with anticoagulants or suffering hemorrhagic diseases.
Export Options
About this article
Cite this article as:
Claudia Sato Ana, A. Andrade Sonia, V. Brito Marlon, Miranda Antonio, Uemura Sampaio Misako, Humberto de Abreu Maffei Francisco and Luiza Vilela Oliva Maria, Effects of Compounds from Passiflora edulis Sims f. flavicarpa Juice on Blood Coagulation and on Proteolytic Enzymes, Protein & Peptide Letters 2012; 19 (5) . https://dx.doi.org/10.2174/092986612800191053
DOI https://dx.doi.org/10.2174/092986612800191053 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer
Reviews on Recent Clinical Trials Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer
Current Cancer Drug Targets STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy Skp2 Inhibitors: Novel Anticancer Strategies
Current Medicinal Chemistry New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Nanotechnology on Duty in Medical Applications
Current Pharmaceutical Biotechnology Celecoxib and Dimethylcelecoxib Block Oxidative Phosphorylation, Epithelial-Mesenchymal Transition and Invasiveness in Breast Cancer Stem Cells
Current Medicinal Chemistry The Neuroendocrine Component in Bladder Tumors
Current Medicinal Chemistry Patent Selections
Recent Patents on Drug Delivery & Formulation Mechanisms of Cytotoxicity of Anticancer Titanocenes
Anti-Cancer Agents in Medicinal Chemistry Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews Editorial (Thematic Issue: Oncoviruses and Head and Neck Cancer: An Impending Facts)
Recent Patents on Biomarkers Discovery of Novel Plant Peptides as Strong Inhibitors of Metalloproteinases
Protein & Peptide Letters Indole-3-Carbinol (I3C) and its Major Derivatives: Their Pharmacokinetics and Important Roles in Hepatic Protection
Current Drug Metabolism Killing the Messenger: Antisense DNA and siRNA
Current Drug Targets Soluble Guanylate Cyclase: A New Therapeutic Target for Fibrotic Diseases
Current Medicinal Chemistry Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy
Current Gene Therapy Caveolin Involvement and Modulation in Breast Cancer
Mini-Reviews in Medicinal Chemistry